X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (222) 222
humans (208) 208
bcr-abl1 (183) 183
hematology (154) 154
chronic myeloid leukemia (145) 145
chronic myelogenous leukemia (126) 126
oncology (123) 123
fusion proteins, bcr-abl - genetics (112) 112
leukemia, myelogenous, chronic, bcr-abl positive - genetics (102) 102
imatinib (101) 101
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (100) 100
leukemia (86) 86
male (81) 81
female (78) 78
chronic myeloid-leukemia (76) 76
hemic and lymphatic diseases (76) 76
adult (73) 73
middle aged (73) 73
protein kinase inhibitors - therapeutic use (70) 70
tyrosine kinase inhibitors (70) 70
imatinib mesylate (61) 61
aged (59) 59
tyrosine (58) 58
cml (57) 57
antineoplastic agents - therapeutic use (52) 52
bcr-abl (50) 50
bcr‐abl1 (47) 47
treatment outcome (47) 47
analysis (46) 46
dasatinib (46) 46
prognosis (45) 45
cancer (44) 44
follow-up (44) 44
philadelphia chromosome (44) 44
genetic aspects (42) 42
mutation (41) 41
minimal residual disease (40) 40
adolescent (38) 38
nilotinib (38) 38
tyrosine kinase inhibitor (38) 38
pyrimidines - therapeutic use (37) 37
young adult (37) 37
chronic myeloid leukaemia (36) 36
care and treatment (35) 35
bcr-abl1 transcript levels (34) 34
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (34) 34
therapy (34) 34
leukemia, myelogenous, chronic, bcr-abl positive - pathology (33) 33
research (33) 33
hematology, oncology and palliative medicine (30) 30
piperazines - therapeutic use (30) 30
polymerase-chain-reaction (30) 30
aged, 80 and over (29) 29
patients (29) 29
kinases (28) 28
myeloid leukemia (28) 28
polymerase chain reaction (28) 28
chronic-phase (27) 27
early molecular response (27) 27
fusion proteins, bcr-abl - metabolism (27) 27
protein-tyrosine kinase (27) 27
recommendations (27) 27
philadelphia-chromosome (26) 26
stem cells (24) 24
antineoplastic agents (23) 23
leukemia, myelogenous, chronic, bcr-abl positive - mortality (23) 23
medicine & public health (23) 23
resistance (23) 23
molecular response (21) 21
precursor cell lymphoblastic leukemia-lymphoma - genetics (21) 21
stem-cells (21) 21
acute lymphoblastic-leukemia (20) 20
antimitotic agents (20) 20
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (20) 20
pathology (20) 20
bcr-abl transcripts (19) 19
benzamides (19) 19
chemotherapy (19) 19
cml patients (19) 19
diagnosed chronic-phase (19) 19
diagnosis (19) 19
drug resistance, neoplasm (19) 19
drug resistance, neoplasm - genetics (19) 19
imatinib mesylate - therapeutic use (19) 19
survival (19) 19
child (18) 18
tyrosine kinase (18) 18
acute lymphocytic leukemia (17) 17
benzamides - therapeutic use (17) 17
drug therapy (17) 17
european leukemianet (17) 17
fusion proteins, bcr-abl - antagonists & inhibitors (17) 17
gene expression (17) 17
genes (17) 17
protein-tyrosine kinases - antagonists & inhibitors (17) 17
rna, messenger - genetics (17) 17
acute lymphoblastic leukemia (16) 16
chromosomes (16) 16
disease-free survival (16) 16
leukemia, myelogenous, chronic, bcr-abl positive - therapy (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


REVISTA DE CHIMIE, ISSN 0034-7752, 09/2019, Volume 70, Issue 9, pp. 3193 - 3196
Chronic myeloid leukemia (CML) is a chronic myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome. Oxidative stress is... 
tyrosine kinase inhibitors | ENGINEERING, CHEMICAL | STEM-CELLS | INSTABILITY | PATHWAY | ANTIOXIDANT STATUS | IMATINIB | BCR-ABL1 transcript | CONTRIBUTES | CHEMISTRY, MULTIDISCIPLINARY | oxidative stress | chronic myeloid leukaemia
Journal Article
British Journal of Haematology, ISSN 0007-1048, 11/2008, Volume 143, Issue 4, pp. 503 - 510
Journal Article
Journal Article
Journal Article
Blood, ISSN 0006-4971, 08/2013, Volume 122, Issue 6, pp. 872 - 884
Journal Article
Blood, ISSN 0006-4971, 02/2014, Volume 123, Issue 9, pp. 1353 - 1360
Journal Article
British Journal of Haematology, ISSN 0007-1048, 03/2013, Volume 160, Issue 5, pp. 630 - 639
The BCR-ABL1 transcript level at 3months can predict long-term outcomes following frontline therapy with Imatinib or Dasatinib in chronic myeloid leukaemia... 
BCR-ABL1 transcript level | Chronic myeloid leukaemia | Second generation tyrosine kinase inhibitor | MESYLATE | INTERFERON | CYTOGENETIC RESPONSE | second generation tyrosine kinase inhibitor | CYTARABINE | HEMATOLOGY | FAILURE | chronic myeloid leukaemia
Journal Article
JNCCN Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 11/2013, Volume 11, Issue 11, pp. 1327 - 1340
The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction... 
TYROSINE KINASE INHIBITORS | BCR-ABL1 TRANSCRIPT LEVELS | CHRONIC-PHASE | ONCOLOGY | MOLECULAR RESPONSES | DASATINIB 100 MG | HARMONIZING CURRENT METHODOLOGY | INTOLERANT PATIENTS | ALPHA PLUS CYTARABINE | CHRONIC MYELOID-LEUKEMIA | BCR-ABL TRANSCRIPTS
Journal Article
Blood, ISSN 0006-4971, 06/2013, Volume 121, Issue 24, pp. 4867 - 4874
Journal Article
British Journal of Haematology, ISSN 0007-1048, 09/2019, Volume 186, Issue 6, pp. 807 - 819
Journal Article
Leukemia, ISSN 0887-6924, 09/2015, Volume 29, Issue 9, pp. 1823 - 1831
Journal Article